Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
780 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04899921 | Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets | terminated | Phase 2 | 1 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT02022982 | PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors | completed | Phase 1 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT02956473 |
| Supine MRI in Breast Cancer Patients Undergoing Upfront Surgery or Receiving Neoadjuvant Therapy |
| completed |
| N/A |
| 57 |
| Dana-Farber Cancer InstituteOTHER |
| 1 |
| Mar 12, 2024 |
| clinicaltrials |
| NCT03051659 | A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer | completed | Phase 2 | 90 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT01466036 | Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | completed | Phase 2 | 61 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT04341311 | Phase I Study of Marizomib + Panobinostat for Children With DIPG(DIPG) | terminated | Phase 1 | 4 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT04071756 | Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions | terminated | Phase 2 | 8 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT04066361 | OPTimizing Treatment Focused Genetic Testing IN Cancer(OPT-IN) | completed | N/A | 301 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT04947917 | Axillary Lymph Node Tattoo Marking Study | terminated | N/A | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT04330716 | Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers(GeneBOPP) | completed | N/A | 269 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT05482074 | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Jan 19, 2024 | clinicaltrials |
| NCT03328091 | Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer (ProGen)(ProGen) | completed | N/A | 662 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT02244463 | A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer | completed | Phase 1 / Phase 2 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT02865135 | Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer | completed | Phase 1 / Phase 2 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT03894891 | Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer | completed | Phase 2 | 6 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT05011279 | Move Together Boston Feasibility Pilot (Sit Less, Move More App for Black Breast Cancer Survivors & At-Risk Relatives) | completed | N/A | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT03557372 | Mathematical Model-Adapted Radiation In Glioblastoma | completed | N/A | 14 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT03364673 | Stepping Into Survivorship: Harnessing Behavioral Economics to Improve Quality of Life in Ovarian Cancer | completed | N/A | 29 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT02971956 | Pembrolizumab in Refractory Advanced Esophageal Cancer | completed | Phase 2 | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01782443 | Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors | completed | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT00834093 | A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma | completed | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT00004180 | Rosiglitazone in Treating Patients With Liposarcoma | completed | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT03761160 | Mobile Health App to Mitigate the Metabolic Effects of Androgen Deprivation Therapy | completed | N/A | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02903381 | A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma | completed | Phase 2 | 8 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT02919969 | Pembrolizumab in Metastatic Anal Cancer | completed | Phase 2 | 38 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT02279394 | E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma | completed | Phase 2 | 51 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT03717402 | Smartphone Technology to Alleviate Malignant Pain (STAMP) | completed | N/A | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 5, 2023 | clinicaltrials |
| NCT04703426 | Sargramostim (GM-CSF) + PD-1 | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | May 22, 2023 | clinicaltrials |
| NCT05774886 | Implantable Microdevice for TNBC - Pilot Study | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | May 18, 2023 | clinicaltrials |
| NCT00790010 | Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma | completed | Phase 1 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT02036476 | Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma | terminated | Phase 2 | 8 | Dana-Farber Cancer InstituteOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT02028988 | Enzalutamide + External Beam Rt For Prostate | completed | Phase 2 | 64 | Dana-Farber Cancer InstituteOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT00114985 | Prostate Immobilization Device Used During Radiation Treatments to Decrease Rectal Bleeding | completed | Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 0 | May 3, 2023 | clinicaltrials |
| NCT01858688 | A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer | completed | N/A | 101 | Dana-Farber Cancer InstituteOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT04879927 | Routine Evaluation of the Social Determinants of Health in Oncology: User-centered Resource Coordination and Engagement(RESOURCE) | completed | N/A | 125 | Dana-Farber Cancer InstituteOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT04354454 | Step Into Support for Endurance and Strength (SISTERS)(SISTERS) | completed | N/A | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04908852 | Feasibility Pilot Exploring Variability in Biomarkers and PROs in AML | completed | — | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT02919670 | A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma | completed | N/A | 114 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT01399658 | Image-Guided Gynecologic Brachytherapy(AMIGO) | completed | Phase 2 | 93 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT02335671 | Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy | completed | N/A | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT01066663 | Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT04661852 | Cabozantinib With Topotecan-Cyclophosphamide | completed | Phase 1 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT02848989 | Qigong For PPSP In Breast Cancer Pain In Breast Cancer Survivors | completed | N/A | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT01746173 | CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma | terminated | Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 30, 2023 | clinicaltrials |
| NCT03999684 | A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma | completed | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT04863157 | Survivor-Sleep Health Information Program | completed | N/A | 16 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT05233215 | GROW (Glioma Specialists Reaching Out With Support) Support | withdrawn | N/A | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT04936243 | TIPOPS (Telemedicine vs In Person Oncology Patient Surveillance) | completed | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 20, 2022 | clinicaltrials |
| NCT02604511 | Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing | completed | Phase 2 | 31 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT03187262 | A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia | completed | Phase 2 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 23, 2022 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials